-- Integrated offering to be highlighted at
Festival of Biologics --
-- Tracey Mullen, MBA, to lead Twist Biopharma
Solutions --
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced an integrated
offering of antibody discovery services available to customers. The
offering combines Twist Biopharma’s synthetic libraries and AI
machine learning with an in vivo immunization approach gained
through the acquisition of Abveris, also known as Twist Boston.
This premium service is able to provide customers with optimized,
development-ready antibody candidates. The combined team will be
led by Tracey Mullen, MBA, who was appointed senior vice president
of biopharma for Twist Bioscience.
“By integrating our platforms into a robust service menu, we now
offer premium throughput, resolution and speed to customers looking
to outsource antibody discovery and optimization,” said Emily M.
Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “When we
acquired Abveris about a year ago, we knew bringing in vivo, in
vitro and in silico platforms together within Twist would truly
differentiate our capability to optimize and deliver
development-ready antibody drug candidates for our customers,
including different antibody formats (bispecific, antibody drug
conjugates (ADCs), monoclonal, VHH, etc.) in multiple therapeutic
areas.”
Dr. Leproust continued, “We have a rapid workflow, a track
record of successfully identifying antibody leads against some of
the hardest to drug biological targets and have discovered
antibodies that are now in clinical trials. This makes Twist a
strong partner for companies who desire a comprehensive and
differentiated approach for both small projects and end-to-end
workflows. We also routinely take on projects where others have
failed to deliver antibodies.”
The newly combined entity, now known as Twist Biopharma
Solutions, combines proprietary technology with years of industry
expertise and scientific excellence to find the best antibody
candidate for given therapeutic targets of interest. Supported by
high-throughput DNA synthesis and IgG antibody production, Twist
constructs large and highly specific synthetic antibody libraries
with discovery beginning with either in vivo or in vitro diversity.
These libraries are then screened to identify the best antibody
candidates for a specific target. Additionally, the integration of
the Abveris in vivo discovery approaches of single B cell screening
and hybridoma discovery enable parallel paths where multiple
technology methods can be leveraged to create a panel of highly
diverse antibody leads with broad epitope coverage. This
multi-pronged approach can increase the likelihood of discovering
highly specific, high affinity functional antibodies by sampling
both natural and synthetic diversity.
Twist offers an end-to-end workflow for centralized antibody
discovery and optimization. Services include:
- Target validation (antigen development, tool antibody
development)
- Hit generation (hybridoma, single B cell, phage display,
alternative in vivo models)
- Lead selection (in vitro characterization, secondary and
tertiary screening, functional screening, high throughput
developability screening, epitope mapping, small and midsize
purification)
- Lead optimization (humanization, affinity maturation)
- Lead characterization (functional profiling, advanced
developability assessment)
Twist Biopharma Solutions, which includes the combined South San
Francisco and Boston biopharma teams, will be led by Tracey Mullen
in her newly appointed role as senior vice president of biopharma.
Aaron Sato, Ph.D., remains integrally involved in Twist Biopharma
Solutions and in his role as chief scientific officer of Twist
Bioscience, extends his expertise across the organization.
“To set the stage for success and best leverage our core
biopharma capabilities to drive revenue growth and acceleration, we
will tap into Tracey’s commercial and operational expertise to take
us forward,” said Dr. Leproust. “With the Factory of the Future
coming along nicely, Tracey is ideally positioned to drive the
customer funnel and focus on optimizing the biopharma team for
revenue generation.”
Tracey joined Twist through the acquisition of Abveris in
November 2021. In April 2022, she took on the position of senior
vice president of operations, driving the completion of the Factory
of the Future in Wilsonville, Oregon, which began shipping products
in January 2023. Prior to Twist, she served as CEO of Abveris.
Before Abveris, she served on the antibody discovery team at Biogen
where she helped implement the technology transfer of the Adimab
yeast display platform for antibody discovery and engineering.
Throughout her tenure at Biogen, Tracey worked to optimize the in
vitro discovery of antibodies to traditionally difficult
therapeutic targets, including leveraging the Adimab platform to
generate antibodies against GPCRs. Previously she worked for a
contract research organization specializing in in vivo antibodies.
She received her B.S. in chemical and biological engineering from
the Massachusetts Institute of Technology and her Executive MBA
from Quantic School of Business and Technology.
Presence at the Festival of Biologics
The integrated offering of antibody discovery services will be
highlighted at the Festival of Biologics occurring March 20-22,
2023 in San Diego. For more information on the integrated offering,
please attend the oral presentation titled, “Writing the Future of
Biologics with an Integrated Offering of Immunization, Libraries,
and Machine Learning” to be given by Aaron Sato, CSO of Twist
Bioscience on Tuesday, March 21 at 12:20 PM PT. Twist will also
have posters and a booth at the event.
About Twist Biopharma Solutions (The Biologics Discovery and
Optimization Division of Twist Bioscience)
Twist Biopharma Solutions combines high-throughput DNA synthesis
technology, deep expertise in antibody engineering and in vivo, in
vitro and in silico discovery methods to provide end-to-end
antibody discovery solutions across the preclinical continuum and
tailored to our partner’s specific needs. By leveraging our unique
ability to manufacture DNA at scale, we can construct proprietary
antibody libraries with discovery beginning with either in vivo or
in vitro diversity. Our Library of Libraries gives our partners an
integral and unbiased resource for antibody therapeutic discovery
and optimization. This precise and rational approach to library
fabrication combined with sophisticated bioinformatics and software
expertise expedites antibody discovery by decreasing risk,
increasing speed, and lowering the failure rate for antibody
therapeutic development. Additionally, in vivo discovery approaches
including single B cell screening and hybridoma discovery enable
parallel paths where multiple technology methods can be leveraged
to create a panel of highly diverse antibody leads. Our automated
screening and panning processes enable us to identify high affinity
leads that our partners can move forward into the clinic. We also
offer supporting development capabilities, including IgG
conversion, expression, purification, biophysical characterization,
and functional characterization.
For more information visit:
https://www.twistbioscience.com/products/antibody-discovery/twist-bioscience-and-abveris
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding future growth and the
capabilities of the Twist Biopharma Solutions offering.
Forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause Twist
Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties relating to COVID-19; the ability to
attract new customers and retain and grow sales from existing
customers; risks and uncertainties of rapidly changing technologies
and extensive competition in synthetic biology that could make the
products Twist Bioscience is developing obsolete or
non-competitive; uncertainties of the retention of significant
customers; the ability of Twist Bioscience to successfully
integrate acquired companies, including Abveris, and to achieve
expected benefits from acquisitions; supply chain and other
disruptions caused by the COVID-19 pandemic or otherwise; risks of
third party claims alleging infringement of patents and proprietary
rights or seeking to invalidate Twist Bioscience’s patents or
proprietary rights; and the risk that Twist Bioscience’s
proprietary rights may be insufficient to protect its technologies.
For a description of the risks and uncertainties that could cause
actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on February
7, 2023 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230309005127/en/
For Twist Bioscience: Angela Bitting SVP, Corporate
Affairs 925- 202-6211 abitting@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Aug 2024 to Sep 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Sep 2023 to Sep 2024